Infinity Pharmaceuticals | INFI - Selling And Administration Expenses


Infinity Pharmaceuticals reported $3.75M in Selling and Administration Expenses for its fiscal quarter ending in June of 2023.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Alterity Therapeutics Limited AUD 2.29M 649.1K Jun/2023
Amgen USD 1.94B 237M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.33M 50K Sep/2025
CSL USD 727M 453M Jun/2025
Eisai JPY 111.72B 7.86B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Grifols EUR 333.1M 157M Sep/2025
Incyte USD 390.41M 61.33M Dec/2025
Infinity Pharmaceuticals USD 3.75M 2.19M Jun/2023
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
J&J USD 6.75B 831M Dec/2025
Novartis USD 3.31B 134M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
TG Therapeutics USD 63.37M 51.33M Sep/2025